Nonmotor symptoms of Parkinson’s disease

Handbook of Parkinson's Disease, Third Edition

Volumn , Issue , 2003, Pages 109-126

  Dewey, Richard B ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 14244253068     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (79)

1. Jellinger KA. Pathology of Parkinson’s disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 14:153-197, 1991.
2. Friedman A, Barcikowska M. Dementia in Parkinson’s disease. Dementia5:12-16, 1994.
3. Girotti F, Soliveri P, Carella F, Piccolo I, Caffarra P, Musicco M, Caraceni T. Dementia and cognitive impairment in Parkinson’s disease. J Neurol Neurosurg Psychiatry 51:1498-1502, 1988.
4. Mayeux R, Stern Y, Rosenstein R, Marder K, Hauser A, Cote L, Fahn S. An estimate of the prevalence of dementia in idiopathic Parkinson’s disease. Arch Neurol 45:260-262, 1988.
5. Mayeux R, Denaro J, Hemenegildo N, Marder K, Tang MX, Cote LJ, Stern Y. A population-based investigation of Parkinson’s disease with and without dementia. Relationship to age and gender. Arch Neurol 49:492-497, 1992.
6. Marder K, Tang MX, Cote L, Stern Y, Mayeux R. The frequency and associated risk factors for dementia in patients with Parkinson’s disease. Arch Neurol 52:695-701, 1995.
7. Aarsland D, Tandberg E, Larsen JP, Cummings JL. Frequency of dementia in Parkinson disease. Arch Neurol 53:538-542, 1996.
8. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P. Risk of dementia in Parkinson’s disease: a community-based, prospective study. Neurology 56:730-736, 2001.
9. Perry EK, Curtis M, Dick DJ, Candy JM, Atack JR, Bloxham CA, Blessed G, Fairbairn A, Tomlinson BE, Perry RH. Cholinergic correlates of cognitive impairment in Parkinson’s disease: Comparisons with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 48:413-421, 1985.
10. Whitehouse PJ, Hedreen JC, White CL, III, Price DL. Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol 13:243-248, 1983.
11. Gaspar P, Gray F. Dementia in idiopathic Parkinson’s disease. A neuropathological study of 32 cases. Acta Neuropathol 64:43-52, 1984.
12. Boller F, Mizutani T, Roessmann U, Gambetti P. Parkinson disease, dementia, and Alzheimer disease: Clinicopathological correlations. Ann Neurol 7:329-335, 1980.
13. Mattila PM, Roytta M, Torikka H, Dickson DW, Rinne JO. Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson’s disease. Acta Neuropathol (Berl) 95:576-582, 1998.
14. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276:2045-2047, 1997.
15. Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, Lee VM, Clark CM, Glosser G, Stern MB, Gollomp SM, Arnold SE. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology 54:1916-1921, 2000.
16. Mattila PM, Rinne JO, Helenius H, Dickson DW, Roytta M. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease. Acta Neuropathol (Berl) 100:285-290, 2000.
17. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 59:102-112, 2002.
18. Perl DP, Olanow CW, Calne D. Alzheimer’s disease and Parkinson’s disease: distinct entities or extremes of a spectrum of neurodegeneration? Ann Neurol44 (suppl 1):S19-31, 1998.
19. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113-1124, 1996.
20. Cummings JL. The dementias of Parkinson’s disease: prevalence, characteristics, neurobiology, and comparison with dementia of the Alzheimer type. Eur Neurol 28 (suppl 1):15-23, 1988.
21. Litvan I, Mohr E, Williams J, Gomez C, Chase TN. Differential memory and executive functions in demented patients with Parkinson’s and Alzheimer’s disease. J Neurol Neurosurg Psychiatry 54:25-29, 1991.
22. Cummings JL, Darkins A, Mendez M, Hill MA, Benson DF. Alzheimer’s disease and Parkinson’s disease: Comparison of speech and language alterations. Neurology 38:680-684, 1988.
23. Ross HF, Hughes TA, Boyd JL, Biggins CA, Madeley P, Mindham RH, Spokes EG. The evolution and profile of dementia in Parkinson’s disease. Adv Neurol 69:343-347, 1996.
24. Samuel W, Caligiuri M, Galasko D, Lacro J, Marini M, McClure FS, Warren K, Jeste DV. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry 15:794-802, 2000.
25. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet356:2031-2036, 2000.
26. Slaughter JR, Slaughter KA, Nichols D, Holmes SE, Martens MP. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 13:187-196, 2001.
27. Yamamoto M. Depression in Parkinson’s disease: its prevalence, diagnosis, and neurochemical background. J Neurol 248 (suppl 3):5-11, 2001.
28. Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG. Depression in Parkinson’s disease. J Nerv Ment Dis 178:27-31, 1990.
29. Gotham AM, Brown RG, Marsden CD. Depression in Parkinson’s disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 49:381-389, 1986.
30. Robins AH. Depression in patients with Parkinsonism. Br J Psychiatry128:141-145, 1976.
31. Starkstein SE, Mayberg HS, Leiguarda R, Preziosi TJ, Robinson RG. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 55:377-382, 1992.
32. Torack RM, Morris JC. The association of ventral tegmental area histopathology with adult dementia. Arch Neurol 45:497-501, 1988.
33. Maricle RA, Nutt JG, Valentine RJ, Carter JH. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson’s disease: a doubleblind, placebo-controlled study. Neurology 45:1757-1760, 1995.
34. Mayeux R, Stern Y, Cote L, Williams JB. Altered serotonin metabolism in depressed patients with parkinson’s disease. Neurology 34:642-646, 1984.
35. Tandberg E, Larsen JP, Aarsland D, Cummings JL. The occurrence of depression in Parkinson’s disease. A community-based study. Arch Neurol53:175-179, 1996.
36. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord 8:193-197, 2002.
37. Maricle RA, Nutt JG, Carter JH. Mood and anxiety fluctuations in Parkinson’s disease associated with levodopa infusion: preliminary findings. Mov Disord 10:329-332, 1995.
38. Brown RG, Marsden CD, Quinn N, Wyke MA. Alterations in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson’s disease. J Neurol Neurosurg Psychiatry 47:454-465, 1984.
39. Stenager EN, Wermuth L, Stenager E, Boldsen J. Suicide in patients with Parkinson’s disease. An epidemiological study. Acta Psychiatr Scand 90:7072, 1994.
40. Klaassen T, Verhey FR, Sneijders GH, Rozendaal N, de Vet HC, van Praag HM. Treatment of depression in Parkinson’s disease: a meta-analysis. J Neuropsychiatry Clin Neurosci 7:281-286, 1995.
41. Goetz CG, Tanner CM, Klawans HL. Bupropion in Parkinson’s disease. Neurology 34:1092-1094, 1984.
42. Montastruc JL, Fabre N, Blin O, Senard JM, Rascol O, Rascol A. Does fluoxetine aggravate Parkinson’s disease? A pilot prospective study. Mov Disord 10:355-357, 1995.
43. Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson’s disease. Mov Disord 12:756-759, 1997.
44. Steur EN. Increase of Parkinson disability after fluoxetine medication. Neurology 43:211-213, 1993.
45. Jimenez-Jimenez FJ, Tejeiro J, Martinez-Junquera G, Cabrera-Valdivia F, Alarcon J, Garcia-Albea E. Parkinsonism exacerbated by paroxetine. Neurology 44:2406, 1994.
46. Caley CF, Friedman JH. Does fluoxetine exacerbate Parkinson’s disease?J Clin Psychiatry 53:278-282, 1992.
47. Richard IH, Kurlan R. A survey of antidepressant drug use in Parkinson’s disease. Parkinson Study Group. Neurology 49:1168-1170, 1997.
48. Douyon R, Serby M, Klutchko B, Rotrosen J. ECT and Parkinson’s disease revisited: a “naturalistic” study. Am J Psychiatry 146:1451-1455, 1989.
49. Figiel GS, Hassen MA, Zorumski C, Krishnan KR, Doraiswamy PM, Jarvis MR, Smith DS. ECT-induced delirium in depressed patients with Parkinson’s disease. J Neuropsychiatry Clin Neurosci 3:405-411, 1991.
50. Oh JJ, Rummans TA, O’Connor MK, Ahlskog JE. Cognitive impairment after ECT in patients with Parkinson’s disease and psychiatric illness. Am J Psychiatry 149:271, 1992.
51. Fink M, Zervas IM. ECT and delirium in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 4:231-232, 1992.
52. Faber R. More on ECT and delirium in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 4:232, 1992.
53. Stein MB, Heuser IJ, Juncos JL, Uhde TW. Anxiety disorders in patients with Parkinson’s disease. Am J Psychiatry 147:217-220, 1990.
54. Vazquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, Garcia-Urra D. “Panic attacks” in Parkinson’s disease. A long-term complication of levodopa therapy. Acta Neurol Scand 87:14-18, 1993.
55. Menza MA, Robertson-Hoffman DE, Bonapace AS. Parkinson’s disease and anxiety: Comorbidity with depression. Biol Psychiatry 34:465-470, 1993.
56. Cash R, Dennis T, L’Heureux R, Raisman R, Javoy-Agid F, Scatton B. Parkinson’s disease and dementia: norepinephrine and dopamine in locus ceruleus. Neurology 37:42-46, 1987.
57. Iruela LM, Ibanez-Rojo V, Palanca I, Caballero L. Anxiety disorders and Parkinson’s disease. Am J Psychiatry 149:719-720, 1992.
58. Richard IH, Szegethy E, Lichter D, Schiffer RB, Kurlan R. Parkinson’s disease: a preliminary study of yohimbine challenge in patients with anxiety. Clin Neuropharmacol 22:172-175, 1999.
59. Berrios GE, Campbell C, Politynska BE. Autonomic failure, depression and anxiety in Parkinson’s disease. Br J Psychiatry 166:789-792, 1995.
60. Richard IH, Schiffer RB, Kurlan R. Anxiety and Parkinson’s disease. J Neuropsychiatry Clin Neurosci 8:383-392, 1996.
61. Dewey RB, Jr., Hutton JT, LeWitt PA, Factor SA. A randomized, doubleblind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 58:1385-1392, 2001.
62. Lieberman A. Managing the neuropsychiatric symptoms of Parkinson’s disease. Neurology 50 (suppl 6):S33-38, 1998.
63. Walsh K, Bennett G. Parkinson’s disease and anxiety. Postgrad Med J 77:8993, 2001.
64. Ludwig CL, Weinberger DR, Bruno G, Gillespie M, Bakker K, LeWitt PA, Chase TN. Buspirone, Parkinson’s disease, and the locus ceruleus. Clin Neuropharmacol 9:373-378, 1986.
65. Higginson CI, Fields JA, Troster AI. Which symptoms of anxiety diminish after surgical interventions for Parkinson disease? Neuropsychiatry Neurop-sychol Behav Neurol 14:117-121, 2001.
66. Magalhaes M, Wenning GK, Daniel SE, Quinn NP. Autonomic dysfunction in pathologically confirmed multiple system atrophy and idiopathic Parkinson’s disease—a retrospective comparison. Acta Neurol Scand 91:98-102, 1995.
67. Appenzeller O, Goss JE. Autonomic deficits in Parkinson’s syndrome. Arch Neurol 24:50-57, 1971.
68. Goetz CG, Lutge W, Tanner CM. Autonomic dysfunction in Parkinson’s disease. Neurology 36:73-75, 1986.
69. Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson’s disease. Eur Neurol 38 (suppl 2):2-7, 1997.
70. Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, Rubin M, Fouad-Tarazi FM. Neurogenic orthostatic hypotension: a doubleblind, placebo-controlled study with midodrine. Am J Med 95:38-48, 1993.
71. Dewey RB, Jr., Rao SD, Holmburg SL, Victor RG. Ergotamine/caffeine treatment of orthostatic hypotension in parkinsonism with autonomic failure. Eur J Neurol 5:593-599, 1998.
72. Goetz CG, Tanner CM, Levy M, Wilson RS, Garron DC. Pain in Parkinson’s disease. Mov Disord 1:45-49, 1986.
73. Factor SA, Brown DL, Molho ES. Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson’s disease. Mov Disord 15:167-169, 2000.
74. Hillen ME, Sage JI. Nonmotor fluctuations in patients with Parkinson’s disease. Neurology 47:1180-1183, 1996.
75. Quinn NP, Koller WC, Lang AE, Marsden CD. Painful Parkinson’s disease. Lancet 1:1366-1369, 1986.
76. Doty RL, Stern MB, Pfeiffer C, Gollomp SM, Hurtig HI. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 55:138-142, 1992.
77. Hawkes CH, Shephard BC, Daniel SE. Olfactory dysfunction in Parkinson’s disease. J Neurol Neurosurg Psychiatry 62:436-446, 1997.
78. Berendse HW, Booij J, Francot CM, Bergmans PL, Hijman R, Stoof JC, Wolters EC. Subclinical dopaminergic dysfunction in asymptomatic Parkinson’s disease patients’ relatives with a decreased sense of smell. Ann Neurol50:34-41, 2001.
79. Pearce RK, Hawkes CH, Daniel SE. The anterior olfactory nucleus in Parkinson’s disease. Mov Disord 10:283-287, 1995.